Journal
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Volume 78, Issue 2, Pages 214-220Publisher
WILEY
DOI: 10.1111/sji.12077
Keywords
-
Categories
Funding
- Danish Cancer Society [DP06075]
- Dagmar Marshall Foundation
- Danish Child Cancer Foundation
- Lundbeck Foundation
- U.S. Office of Naval Research
- National Cancer Institute (NCI) [U24-CA76518]
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL0692 94]
- NCI
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637 015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen, Inc.
- Anonymous donation to the Medical College of Wisconsin
- Astellas Pharma US, Inc.
- Baxter International, Inc.
- Bayer Health-Care Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- BioMarin Pharmaceutical, Inc.
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix, GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc.
- CytoTherm
- DOR BioPharma, Inc.
- Dynal Biotech, an Invitrogen Company
- Eisai, Inc.
- Enzon Pharmaceuticals, Inc.
- European Group for Blood and Marrow Transplantation
- Gamida Cell, Ltd.
- GE Healthcare
- Genentech, Inc.
- Genzyme Corporation
- Histogenetics, Inc.
- HKS Medical Information Systems
- Hospira, Inc.
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co., Ltd.
- Leukemia & Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- MGI Pharma, Inc.
- Michigan Community Blood Centers
- Millennium Pharmaceuticals, Inc.
- Miller Pharmacal Group
- Milliman USA, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics, Inc.
- Otsuka America Pharmaceutical, Inc.
- Pall Life Sciences
- Pfizer Inc.
- Saladax Biomedical, Inc.
- Schering Corporation
- Society for Healthcare Epidemiology of America
- Soligenix, Inc.
- StemCyte, Inc.
- StemSoft Software, Inc.
- Sysmex America, Inc.
- THERAKOS, Inc.
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals, Inc.
- ViraCor Laboratories
- ViroPharma, Inc.
Ask authors/readers for more resources
Interleukin-7 (IL-7) is essential for T cell development in the thymus and maintenance of peripheral T cells. The -chain of the IL-7R is polymorphic with the existence of SNPs that give rise to non-synonymous amino acid substitutions. We previously found an association between donor genotypes and increased treatment-related mortality (TRM) (rs1494555G) and acute graft versus host disease (aGvHD) (rs1494555G and rs1494558T) after hematopoietic cell transplantation (HCT). Some studies have confirmed an association between rs6897932C and multiple sclerosis. In this study, we evaluated the prognostic significance of IL-7R SNP genotypes in 590-recipient/donor pairs that received HLA-matched unrelated donor HCT for haematological malignancies. Consistent with the primary studies, the rs1494555GG and rs1494558TT genotypes of the donor were associated with aGvHD and chronic GvHD in the univariate analysis. The Tallele of rs6897932 was suggestive of an association with increased frequency of relapse by univariate analysis (P=0.017) and multivariate analysis (P=0.015). In conclusion, this study provides further evidence of a role of the IL-7 pathway and IL-7R SNPs in HCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
